Imunon (IMNN) Notes Payables (2010 - 2023)

Imunon's (IMNN) quarterly Notes Payables came in at $2.2 million in Q1 2023, up 53.1% on a QoQ basis from $1.4 million in Q4 2022.

Imunon (IMNN) Notes Payables (2010 - 2023) Analysis & Trends

Imunon (IMNN) has 13 years of Notes Payables data on file, last reported at $2.2 million in Q1 2023.

Quarterly Notes Payables changed N/A year-over-year to $2.2 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $2.2 million (changed N/A YoY) and the FY2022 annual result came in at $1.4 million, changed N/A from the prior year.
Notes Payables climbed to $2.2 million in Q1 2023, from $1.4 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $4.4 million in Q2 2020 to a low of $416476.0 in Q3 2020.
A 5-year average of $1.7 million and a median of $1.6 million in 2021 frame the typical range for Notes Payables.
Annual changes were most pronounced in 2020 — Notes Payables slumped 39.32% — and 2021, when it declined 19.31%.
Tracing IMNN's Notes Payables over 5 years: stood at $1.8 million in 2019, then tumbled by 39.32% to $1.1 million in 2020, then jumped by 64.46% to $1.8 million in 2021, then retreated by 22.42% to $1.4 million in 2022, then soared by 53.1% to $2.2 million in 2023.
The last three Notes Payables figures came in at $2.2 million (Q1 2023), $1.4 million (Q4 2022), and $670513.0 (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-
10	Imunon	8.60 Mn	8.60 Mn	-

Download Data